心血管疾患におけるATF4:新たな治療標的
Luning Qin1, Ruolan Chen1, Chao Huang2
1Department of Cardiology, the Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao 266100, Shandong, China.
Biochemical pharmacology
|January 12, 2026
まとめ
活性化転写因子4(ATF4)は、小胞体ストレスとオートファジーを介して細胞運命を調節します。その心血管疾患メカニズムを理解することは、ATF4代謝-死軸を標的とする新しい治療法につながる可能性があります。
科学分野:
- 分子生物学
- 心血管研究
- 細胞ストレス応答
背景:
- 活性化転写因子4(ATF4)は、ATF/CREBファミリーにおける主要な調節因子であり、小胞体ストレス(ERS)、オートファジー、およびレドックスネットワークを介して細胞運命に影響を与えます。
- 心血管恒常性の維持はATF4のバランスの取れた機能に依存していますが、心血管疾患(CVDs)におけるその調節メカニズムは完全には理解されていません。
研究 の 目的:
- 心血管疾患(CVDs)におけるATF4の動的な調節ネットワークを体系的に解明すること。
- ATF4の相互作用マップを構築すること。
- ATF4標的CVD治療を進歩させるための重要な研究領域を特定すること。
主な方法:
- ATF4調節ネットワークの体系的な解明。
- ATF4相互作用マップの構築。
- 主要な研究ギャップと将来の方向性の特定。
主要な成果:
- 本研究は、CVDsの文脈におけるATF4の複雑な調節ネットワークの概要を説明しています。
- ATF4の相互作用関係マップが構築されました。
- 3つの重要な研究領域が強調されました:細胞型特異的エピジェネティック調節、時空間特異的ATF4活性化戦略、および組織標的ATF4モジュレーター。
結論:
- ATF4の細胞型特異的エピジェネティック調節、精密介入戦略、および標的モジュレーターに関するさらなる研究が不可欠です。
- これらの分野の進歩は、ATF4を介した代謝-死軸を標的とすることにより、CVDsの新しい治療戦略をもたらすと期待されています。
さらに関連する動画
関連する概念動画
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
429
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
429
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
433
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433
Atherosclerosis I: Introduction
890
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
890


